SynBiotic Toekomstige groei
Future criteriumcontroles 5/6
SynBiotic is forecast to grow earnings and revenue by 107% and 39.7% per annum respectively. EPS is expected to grow by 107.3% per annum. Return on equity is forecast to be 7.7% in 3 years.
Belangrijke informatie
107.0%
Groei van de winst
107.3%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 18.0% |
| Inkomstengroei | 39.7% |
| Toekomstig rendement op eigen vermogen | 7.7% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 17 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 34 | 2 | 3 | 3 | 3 |
| 12/31/2025 | 26 | 0 | 1 | 2 | 3 |
| 12/31/2024 | 16 | -2 | -3 | -3 | 3 |
| 12/31/2023 | 4 | -11 | -3 | -3 | N/A |
| 12/31/2022 | 8 | -24 | -7 | -7 | N/A |
| 12/31/2021 | 9 | -13 | -6 | -5 | N/A |
| 12/31/2020 | 5 | -1 | -3 | -1 | N/A |
| 12/31/2019 | N/A | 0 | 0 | 0 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: SBX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Winst versus markt: SBX is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: SBX is expected to become profitable in the next 3 years.
Omzet versus markt: SBX's revenue (39.7% per year) is forecast to grow faster than the German market (5.5% per year).
Hoge groei-inkomsten: SBX's revenue (39.7% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: SBX's Return on Equity is forecast to be low in 3 years time (7.7%).